GPCR dimers/oligomers and their regulation by ligands
| Receptor | Reference |
|---|---|
| Ligand-regulated | |
| Adenosine A1 | Franco et al., 1996 |
| β2-adrenoceptor | Gurdal et al., 1996; Hebert et al., 1996; Hebert et al., 1998; Angers et al., 2000, 2001 |
| Bradykinin B2 | AbdAlla et al., 1999 |
| Chemokine CCR5 | Vila-Coro et al., 2000 |
| δ-Opioid | Cvejic and Devi, 1997 |
| GnRH receptor | Cornea et al., 2001; Kroeger et al., 2001 |
| LH receptor | Roess et al., 2000 |
| Muscarinic M2 | Hirschberg and Schimerlick, 1994 |
| TRH receptor | Kroeger et al., 2001 |
| Adenosine A1 + Dopamine D1 10-a | Gines et al., 2000 |
| Somatostatin SSTR1 + SSTR5 | Rocheville et al., 2000a,b |
| Not ligand-regulated | |
| α-Factor | Overton and Blumer, 2000 |
| δ-Opioid | McVey et al., 2001 |
| Dopamine D1 | George et al., 1998 |
| Muscarinic M2 | Park et al., 2001 |
| Muscarinic M3 | Zeng and Wess, 1999 |
| Vasopressin V2 | Schulz et al., 2000 |
| κ + δ opioid10-a | Jordan and Devi, 1999 |
| Regulation by ligands not determined | |
| α2-adrenoceptor | Maggio et al., 1993a |
| AT1 angiotensin | Monnot et al., 1996 |
| β1-adrenoreceptor | Fowler et al., 1999 |
| β2-adrenoceptor | Limbird et al., 1975; Venter and Fraser, 1983 |
| Bradykinin B2 | Pizard et al., 1998 |
| δ-Opioid | Polastron et al., 1994 |
| D2 receptor | Ng et al., 1996;Zawarynski et al., 1998; Scarselli et al., 2000; Armstrong and Strange, 2001; Lee et al., 2000 |
| D3 receptor | Nimchinsky et al., 1997; Karpa et al., 2000 |
| Glucagon receptor | Herberg et al., 1984 |
| GnRH | Grosse et al., 1997 |
| Histamine | Sinkins et al., 1993; Sinkins and Wells, 1993 |
| Muscarinic | Hedlund et al., 1982; Avissar et al., 1983 |
| Muscarinic M1 | Potter et al., 1988 |
| Muscarinic M2 | Mattera et al., 1985; Boyer et al., 1986; Potter et al., 1991; Wregget and Wells, 1995; Chidiac et al., 1997 |
| Muscarinic M3 | Maggio et al., 1993b |
| mGluR1 | Ray and Hauschild, 2000 |
| V2 vasopressin | Zhu and Wess, 1998 |
| 5-HT1B + 5-HT1D | Ng et al., 1993; Xie et al., 1999 |
| AT1angiotensin + bradykinin B2 10-a | AbdAlla et al., 2000 |
| Adenosine A1 +P2Y1 10-a | Yoshioka et al., 2001 |
| β2 +δ-opioid10-a | Jordan et al., 2001 |
| GABABR1 +R210-a | Kaupmann et al., 1998; White et al., 1998; Kuner et al., 1999 |
| μ +δ-opioid10-a | Vaught et al., 1982; George et al., 2000; Gomes et al., 2000 |
| mGluR1α + adenosine A1 10-a | Ciruela et al., 2001 |
↵10-a Heterodimer displays novel pharmacological properties compared with the individually expressed receptors.